© 2021 MJH Life Sciences and HCPLive - Clinical news for connected physicians. All rights reserved.
© 2021 MJH Life Sciences™ and HCPLive - Clinical news for connected physicians. All rights reserved.
December 13, 2009
A study recommends use of trastuzumab concurrently with the taxane portion of chemotherapy for breast cancer patients.
In the BIG 1-98 trial, high-risk patients did best with 5 years of letrozole and low-risk patients did similarly well with any of the trial%u2019s regimens.
Many patients who chose mastectomy were not at increased breast-cancer risk and may have done so based on a failed attempt at breast-conservation surgery.
Anthracycline chemotherapy plus trastuzumab outperformed anthracycline alone, and performed similarly to a non-anthracycline regimen in breast cancer patients.
For patients with early breast cancer, peripheral neurotoxicity is an unfortunate side effect of treatment with taxanes, but there may be a silver lining.
December 12, 2009
Doubling the dose of fulvestrant increases the time to disease progression in the treatment of postmenopausal women with breast cancer.
The multi-targeted kinase inhibitor sorafenib, approved to treat kidney and liver cancer, may also benefit patients with metastatic breast cancer.
About 10 months of neoadjuvant letrozole is optimal for breast-conserving surgery in patients with early breast cancer.
Updated results confirm that addition of bevacizumab to docetaxel as first-line breast cancer treatment improves survival and response rates.
Lung cancer deaths are significantly less common in breast cancer patients who are treated with anti-estrogens.